Zoetis Inc.

What they do

Zoetis discovers, develops, manufactures and commercializes animal health products across eight core species (dogs, cats, horses, cattle, swine, poultry, fish, sheep) and seven major product categories including parasiticides, vaccines, dermatology, anti-infectives and diagnostics. It operates two geographic segments: U.S. and International, selling approximately 300 product lines, primarily by prescription through veterinarians, with a smaller share through retail and e-commerce. The company also runs a Client Supply Services contract manufacturing organization and human health diagnostics products, together about 1% of revenue.

Revenue drivers

• U.S. segment — Generated $5,097 million, or 54% of 2025 revenue, with a mix weighted 83% companion animal and 17% livestock.
• International segment — Generated $4,254 million, or 45% of 2025 revenue, with 56% companion animal and 44% livestock; Brazil ($393M), Australia ($329M), the UK ($325M) and Germany ($236M) are among the largest markets.
• Companion animal products — Represented approximately 70% of 2025 revenue, spanning parasiticides (Simparica line), dermatology, osteoarthritis pain and diagnostics.
• Livestock products — Represented approximately 29% of 2025 revenue, with demand tied to animal protein production, producer economics and disease outbreak activity.

Recent performance

Second quarter 2026 revenue was $2.5 billion, flat versus the prior-year quarter and down 1% on an organic operational basis, with net income of $691 million and diluted EPS of $1.65, down 5% and up 1% respectively on a reported basis. U.S. segment revenue fell 7% to $1.3 billion on softer companion animal demand, with companion animal sales down 11% on dermatology and Simparica Trio price sensitivity, generic competition on Cerenia and Convenia and lower Librela sales, partly offset by livestock growth of 23%. International revenue rose 8% to $1.2 billion, led by parasiticides and diagnostics plus launches of OA pain products Lenivia and Portela. First-half 2026 revenue was $4,730 million versus $4,672 million a year earlier, with net income of $1,292 million versus $1,328 million.

Strategy

Zoetis is adapting its commercial approach to a more pressured companion animal market through targeted investments, accelerated innovation and business development. Management continues to emphasize a diversified portfolio, citing strength in Livestock and Diagnostics, and points to a pipeline including more than 12 potential blockbusters over the coming years. The company is also aligning the fiscal years of its non-U.S. subsidiaries in 2026, eliminating a one-month reporting lag. Consistent with past practice, growth has been driven substantially by life-cycle innovation on existing brands, such as additional claims and species for the Simparica franchise.

Risks

• Companion animal demand weakness — Lower clinic visits and pet owner price sensitivity reduced demand in the second quarter of 2026, contributing to an 11% decline in U.S. companion animal product sales.
• Generic competition — Generic entry on the Cerenia and Convenia brands contributed to the U.S. revenue decline in the second quarter of 2026.
• Tariffs and trade measures — The company cites additional U.S. tariffs imposed from early 2025 and reciprocal tariffs by other nations, including exposure to China, Canada and the European Union.
• Intense competition in key categories — Management flagged heightened competitive pressure on the dermatology franchise and Simparica Trio in the U.S. in the second quarter of 2026.

Outlook

Management revised full year 2026 revenue guidance to $9.120–$9.320 billion, implying organic operational revenue growth of (3)% to (1)%, and revised adjusted net income guidance to organic operational growth of (9)% to (5)%. Adjusted diluted EPS guidance was reduced to $6.15–$6.25. The company attributes the revision to the more pressured companion animal market while citing continued strength in Livestock and Diagnostics and confidence in long-term animal health fundamentals.